Clinical trials: Cancer, Metastatic
Hepatocellular Carcinoma
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
This study will evaluate the safety, tolerability, pharmacokinetic and efficacy of fisogatinib (formerly known as BLU-554) in combination with CS1001 in patients with locally advanced or metastatic hepatocellular carcinoma (HCC)
- Trial name
- NCT04194801
- Testing
- Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg, Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg, Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- CStone Pharmaceuticals
Metastatic Melanoma, Head Neck Cancer
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD-101 injections in combination with intravenous pembrolizumab in…
- Trial name
- NCT02521870
- Testing
- SD-101(1), Pembrolizumab, SD-101(2)
- Where
- 47 sites in United States, Australia and 2 more
- Volunteers
- 241 people
- Sponsor
- Dynavax Technologies Corporation
Prostate Cancer
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer…
- Trial name
- POSEIDON (NCT01313273)
- Testing
- Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and LHRH-a
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Ipsen
Colorectal Cancer, Diarrhea
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment with irinotecan. PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing diarrhea in patients who are…
- Trial name
- NCT00006269
- Testing
- irinotecan hydrochloride, octreotide acetate
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Novartis
Breast Cancer
Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy directed at the head is effective in preventing brain metastases in patients with advanced cancer.
- Trial name
- NCT00639366
- Testing
- trastuzumab, chemotherapy, radiation therapy
- Where
- 19 sites in United Kingdom
- Volunteers
- 390 people
- Sponsor
- Anglo Celtic Cooperative Oncology Group
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Breast Cancer Metastatic
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
- Trial name
- NCT01876251
- Testing
- PF-03084014, Docetaxel
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 30 people
- Sponsor
- Pfizer
Metastatic Cancer
Monoclonal Antibody Therapy in Treating Patients With Brain Metastases
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002751
- Testing
- monoclonal antibody Me1-14 F(ab')2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
This study will enroll participants with nonresectable or metastatic cholangiocarcinoma with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have previously received at least 1, but no more than 2, prior regimens for…
- Trial name
- NCT06081829
- Testing
- Ivosidenib
- Where
- 7 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Servier
HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression
Testing a New Imaging Agent to Identify Cancer
The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.
- Conditions
- HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression, HER2-positive Metastatic Breast Cancer
- Trial name
- NCT04692831
- Testing
- 89Zr-ss-pertuzumab PET/CT
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma of Unknown Primary Origin
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00936702
- Testing
- carboplatin, everolimus, paclitaxel
- Where
- 141 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer
Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.
- Trial name
- NCT03700437
- Testing
- Fasting-Mimicking Diet
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Indiana University
Locally Advanced or Metastatic Breast Cancer
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the…
- Trial name
- IRENE (NCT03027245)
- Testing
- Eribulin
- Where
- 65 sites in Germany
- Volunteers
- 353 people
- Sponsor
- Eisai GmbH
Esophageal Cancer, Gastric Cancer
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD…
- Trial name
- NCT00215995
- Testing
- Cisplatin, Irinotecan, ZD 1839
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer
Adjuvant Effect of Chloroquine on Gemcitabine
The purpose of this study is to evaluate the safety by defining the maximum tolerated dose (MTD) of Choloroquine when combined with Gemcitabine, and to evaluate preliminary efficacy of combined systemic Gemcitabine and…
- Trial name
- NCT01777477
- Testing
- Chloroquine, Gemcitabine
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- University of Zurich
Colorectal Cancer, Metastatic Cancer
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Trial name
- NCT00020501
- Testing
- FOLFIRI regimen, floxuridine, fluorouracil
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cervical Cancer
A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Efficacy and safety of Tislelizumab combined with Bevacizumab and chemotherapy in patients with persistent, recurrent or metastatic cervical cancer.
- Trial name
- NCT05247619
- Testing
- Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Zhejiang Cancer Hospital
Colorectal Cancer Metastatic
Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients
Study Design: Multicenter, non randomized, open label phase II study designed to evaluate the efficacy and safety of Gemcitabine/Pemetrexed combination. Enrollment period: 18 months.
- Trial name
- NCT01909830
- Testing
- Arm A : Gemcitabine + Pemetrexed
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Breast Cancer
Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer
Select 600 cases of women with breast cancer of triple negative or Her-2 positive or with more than 4 axillary lymph node metastasis. All the patients were accepted the chemotherapy of Anthracycline and/or Taxane.
- Trial name
- NCT01662128
- Testing
- Xeloda
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Tianjin Medical University
Squamous Non Small Cell Lung Cancer
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous NSCLC…
- Trial name
- NCT04033354
- Testing
- HLX10, carboplatin and nab paclitaxel
- Where
- 92 sites in United States, China and 5 more
- Volunteers
- 537 people
- Sponsor
- Shanghai Henlius Biotech